(2S, 3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl4-oxo-2-(4-[1,2,4]triazolo[1,5-a]pyridin-6-ylphenyl)butanamide:: A selective α-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

被引:111
作者
Edmondson, Scott D. [1 ]
Mastracchio, Anthony [1 ]
Mathvink, Robert J. [1 ]
He, Jiafang [1 ]
Harper, Bart [1 ]
Park, You-Jung [1 ]
Beconi, Maria [1 ]
Di Salvo, Jerry [1 ]
Eiermann, George J. [1 ]
He, Huaibing [1 ]
Leiting, Barbara [1 ]
Leone, Joseph F. [1 ]
Levorse, Dorothy A. [1 ]
Lyons, Kathryn [1 ]
Patel, Reshma A. [1 ]
Patel, Sangita B. [1 ]
Petrov, Aleksandr [1 ]
Scapin, Giovanna [1 ]
Shang, Jackie [1 ]
Roy, Ranabir Sinha [1 ]
Smith, Aaron [1 ]
Wu, Joseph K. [1 ]
Xu, Shiyao [1 ]
Zhu, Bing [1 ]
Thornberry, Nancy A. [1 ]
Weber, Ann E. [1 ]
机构
[1] Merck & Co Inc, Merck Res Labs, Rahway, NJ 07065 USA
关键词
D O I
10.1021/jm060015t
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of beta-substituted biarylphenylalanine amides were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the metabolic profile of early analogues led to the discovery of (2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2(4-[1,2,4] triazolo[1,5-a]pyridin-6-ylphenyl)butanamide (6), a potent, orally active DPP-4 inhibitor (IC50 = 6.3 nM) with excellent selectivity, oral bioavailability in preclinical species, and in vivo efficacy in animal models. Compound 6 was selected for further characterization as a potential new treatment for type 2 diabetes.
引用
收藏
页码:3614 / 3627
页数:14
相关论文
共 52 条
[51]   Metabolic activation of fluoropyrrolidine dipeptidyl peptidase-IV inhibitors by rat liver microsomes [J].
Xu, SY ;
Zhu, B ;
Teffera, Y ;
Pan, DE ;
Caldwell, CG ;
Doss, G ;
Stearns, RA ;
Evans, DC ;
Beconi, MG .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (01) :121-130
[52]  
2003, J MED CHEM, V46, P2774